

Please find below a summary of changes made to the BSW joint formulary (by the previous individual formulary groups (BCAP, 3Ts and SFT) since March 2020.

From September 2020, changes to the BSW joint formulary will be agreed and minuted through the monthly Area Prescribing Committee (APC) meetings and communicated via newsletter, teamsnet and via the APC recent decisions tab [here](#).

The BSW joint formulary is still under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading please contact us at bswccg.formulary@nhs.net

New and Updated Shared Care Agreements

New - SCA: [DOACS for the OFF-LABEL treatment of cancer associated thrombosis \(RUH patients only\)](#)

Updated - SCA: [LMWH for the OFF-LABEL treatment of cancer associated thrombosis \(RUH patients only\)](#)

Updated – SCA: [BSW Paediatric and adolescent ADHD shared care \(methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine\)](#)

Updated – SCA: [BSW adult ADHD \(methylphenidate, atomoxetine and lisdexamfetamine\)](#)

Updated – SCA: [Ibandronic acid as adjuvant therapy for postmenopausal women with early breast cancer \(RUH and GWH patients\)](#) Updated to include Great Western Hospital, update logos, costs and specialist responsibilities May 2020.

New – SCA: [Methotrexate Sub Cut Injection \(Adult Rheumatology Patients\) \(GWH patients only\)](#)

New and Updated Prescribing Guidelines

Updated - [BSW Chronic Migraine Pathway for Adults](#) includes sodium valproate and candesartan (Amber TLS) and info about approved use of fremanezumab (Red TLS) in line with [NICE TA631](#)

New - [BSW Ranitidine Supply Disruption Guidance](#)

Updated – [Bisphosphonate Length of Treatment: Guidelines for GPs \(RNHRD patients only\)](#)

Updated - [BSW Guidance for the use of Proton Pump Inhibitors \(PPIs\) in Adults](#)

New - BSW Nutrition Resource Pack for Care Homes ([FULL guidance](#)) and ([SUMMARY guidance](#))

Updated - [BSW Acne Prescribing Guidelines - Clinical Management in Primary Care](#)

Updated – BSW Management of Infection Guidance for Primary Care; [FULL](#) and [SUMMARY](#) versions. *Includes updates in line with NICE for CAP with COVID and Impetigo*

Updated - [BSW Sacubitril Valsartan for Heart failure](#) *updates to local contact details*

Updated - [BSW Lidocaine 5% Medicated Plasters \(Ralvo®\) Guidance for non-cancer pain in adults](#)

New – [Swindon and GWH Community Palliative & End of Life Care Support](#)

New additions to the BSWformulary

- [Crystacide®](#) (Hydrogen peroxide 1% cream) added in line with NICE guidance as first line option for impetigo. Green TLS. *See updated antibiotic prescribing guidelines below.*
- [Epiduo gel](#) (Adapalene 0.3% and Benzoyl Peroxide 2.5%) new strength added in addition to existing 0.1%/2.5% product. Green TLS. *See updated acne guidelines below.*
- [Soprabec inhaler](#) added as an additional, cost-effective, first line beclomethasone inhaler alongside Clenil (added due to instabilities in the supply chain). Green TLS.
- [Syonell and Belvo](#) brands of valproic acid added due to stock shortages of Depakote (Valproic acid) following advice from AWP. Amber TLS.
- [Imvaggis® 0.03 mg estriol pessaries](#) Local treatment of vaginal symptoms of estrogen deficiency in postmenopausal women. Green TLS. **Wiltshire and BaNES patients only.** *Outstanding action to update HRT guidance.*
- [Hylonight](#) preservative free eye ointment (new name for Vit-A-Pos; ingredients remain the same). Green TLS.
- [Calvive 1000 Effervescent Tablets](#) (new name for Sandocal 1000 effervescent tablets; ingredients remain the same). Amber TLS.

New indications for existing drugs on BSWformulary

- New indications added for [sodium valproate and for candesartan](#). Off license use for migraine prophylaxis. Amber TLS. *See updated guidelines below.*
- New indication for [letrozole tablets](#). Added as second line treatment of patient with anovulatory infertility unresponsive to clomifene citrate. Red TLS (**RUH/GWH patients only**).

- Peptac remains first line compound alginate preparation but [Gaviscon Advance](#) is specifically licensed for laryngopharyngeal reflux and can be used first line for this indication (usually following SALT assessment). Green TLS.
- [Risperidone \(oral\)](#) added for short-term aggression/agitation. Amber TLS.
- [Duloxetine capsules](#) added for indication of depression in addition to current indication of mixed anxiety/depression. Amber TLS.

Minor changes to previous (BCAP/3TS/ICID) formularies to align for BSWformulary

- [Oralieve](#) 50mL spray included as option for all of BSW for treatment of dry mouth. Green TLS.
- [Methylprednisolone tablets](#) aligned as Amber TLS. (*Ongoing action to revisit GWH prescribers guidance - Methylprednisolone for MS relapse*).
- [Ibandronic acid tablets](#) aligned as third line bisphosphonate for osteoporosis. Green TLS
- [Fludrocortisone tablets](#) aligned as Amber TLS.

Changes in Traffic Light Status

- [Colesevelam tablets](#) Provisional change from AwSCA to Green TLS agreed for **BaNES, West Wilts and Swindon patients (those seen at RUH/GWH)**. This is due to ongoing supply issues with colestyramine and will be reviewed in line with availability.
- [Podophyllotoxin](#) 0.5% solution 3mL and 0.15% cream 5g. Reinstated from Red to Green TLS as option for treatment of genital warts now this is back in stock as a licensed product.
- [Phytomenadione 10mg tablets](#) changed from green to Red TLS **for new patients**. Only unlicensed versions of the tablets are available now which are prohibitively expensive in primary care. Existing patients in primary care should be reviewed.
- [Heparin Sodium Patency Solution 200iu/2mls](#) when used for flushing and locking TIVaDs in line with [safe prescribing guidance](#). Amber TLS. **BaNES patients only**.

Non-formulary reminders

- [Diamorphine is no longer considered a formulary choice due to shortages](#) but existing stocks can and should be used where appropriate. Also see SPS memo [here](#)
- [Intra-articular hyaluronic acid \(hyaluronan\) injections](#) for the treatment of osteoarthritis included as **non-formulary**. E.g. Durolane®, Euflexxa®, Fermathron®, Hyalgan®, Orthovisc®, Ostenil®, Ostenil Plus®, RenehaVis®, Suplasyn®, Synocrom®, Synopsis®.
- [Commercial eye hygiene preparations](#) for blepharitis and dietary supplements for Age-related Macular Degeneration included as **non-formulary**.

What BSW CCG formulary team are working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the over active bladder (OAB) pathway
- Producing a consensus statement for newly license liquid omeprazole
- Oxycodone and fentanyl preparations: Aligning TLS across BSW for different indications
- Updating the Vitamin D guidance
- Updating the Vitamin B12 guidance
- Updating the domperidone guidance
- Updating the pain management documents
- Reviewing the use of Cox-2 inhibitors across BSW and producing guidance
- Producing guidance on aphthous ulcers
- Reviewing the use of rifampicin across BSW
- Reviewing the use of LMWH across BSW
- Position statements on various devices
- Aligning Shared Care Agreements across BSW starting with document on DMARD monitoring